Objective The purpose of this guideline is to recommend systemic therapy options for women with recurrent epithelial ovarian cancer, including fallopian tube and primary peritoneal cancers.
INTRODUCTION
In Canada, ovarian cancer is the 5th leading cause of cancer death among women and the leading cause of gynecologic cancer mortality. New cases of ovarian cancer were estimated to reach 2800 in Canada in 2015 1 . Ovarian cancer is usually diagnosed at an advanced stage, and most patients experience relapse after primary therapy, resulting in a survival rate of approximately 10%-30% 2 .
One of the most frequently documented predictors of response to chemotherapy in women with recurrent ovarian cancer is the platinum-free interval, defined as the period of time from the last dose of platinum-based therapy until disease progression 3 . However, some patients become increasingly resistant to platinum-based therapies over time, and some women respond to multiple lines of treatment. Although responsiveness to platinum-based therapies would be more accurately viewed as occurring on a continuum 4 , the platinum sensitivity of patients is, for the purposes of treatment planning and research, often stratified as follows 5 :
■ Platinum-sensitive patients
Patients with a platinum-free interval of 6 months or longer (that is, patients with disease that relapses 6 or more months after completion of initial therapy) ■ Platinum-resistant patients
Patients with a platinum-free interval of less than 6 months (that is, patients whose disease relapses less than 6 months after completion of initial therapy) ■ Platinum-refractory patients Patients whose disease progressed during previous platinum-containing therapy
Many patients with recurrent ovarian cancer do not survive their cancers, and as a result, the duration of survival (prolonged pfs) and quality of life (qol) are important outcomes. In this population, pfs is therefore a valid study endpoint. With those principles in mind, the Working Group chose pfs as one of the primary outcomes of interest.
RESEARCH QUESTION
What is the optimal systemic therapy for women with recurrent ovarian cancer who have previously received platinum-based chemotherapy?
These study comparisons were considered: any systemic therapy option compared with another systemic therapy option, and any systemic therapy option compared with placebo.
TARGET POPULATION
The target population consists of women with recurrent epithelial ovarian cancer who have previously received platinum-based chemotherapy. Specific subgroups of interest in the target population are identified based on their response to therapy.
INTENDED USERS
The intended users of this guideline are gynecologic oncologists or medical oncologists in the prov ince of Ontario.
DEVELOPMENT OF RECOMMENDATIONS
The Program in Evidence-Based Care (pebc) at Cancer Care Ontario (cco) produces evidence-based and evidenceinformed guidance documents using the methods of the practice guidelines development cycle 6, 7 . The process includes a systematic review, interpretation of the evidence by the Working Group, draft recommendations, internal review by content and methodology experts, and external review by Ontario clinicians and other stakeholders.
The project was led by a sma ll Work ing Group consisting of members of t he Gy necologic Ca ncer Disease Site Group. The Working Group was responsible for reviewing the evidence base, drafting the guideline recommendations, and responding to comments received during the document review process. The Working Group members had expertise in gynecologic oncology, medical oncology, and health research methodology.
INTERNAL AND EXTERNAL REVIEW
Before submission of the draft report for external review, the systematic review and the guideline recommendations were reviewed by the pebc's Report Approval Panel, which consists of 2 members, one of whom is an oncologist with expertise in clinical and methodology issues. The pebc's Report Approval Panel reviewed the draft systematic review and the updated guideline and provided feedback.
The external review by clinical practitioners used two processes: a targeted peer review, and a professional consultation.
In the targeted peer review, 4 reviewers from Ontario (considered to be clinical or methodology experts on the topic) agreed to participate. They reviewed a draft report and answered a questionnaire evaluating the methods, results, and interpretive summary used to inform the draft recommendations.
In the professional consultation, feedback was obtained through a brief online survey of medical and gynecologic oncologists who treat ovarian cancer in Ontario.
The draft systematic review of guidelines and the updated guideline recommendations were distributed to health care providers in the province of Ontario. Results of those sources of feedback can be found in the full guideline report on the cco Web site: https://www. cancercare.on.ca/toolbox/qualityguidelines/diseasesite/ gynecologic_cancer/. 
LITERATURE SEARCH RESULTS

Search for Existing Guidelines, Systematic Reviews, and Primary Literature
A search of the medline and embase databases and the Cochrane Database of Systematic Reviews for systematic reviews and primary studies was conducted from 1 April 2011 to 30 May 2017.
Study Selection Criteria and Process
Included studies are those that examined systematic therapy for women with epithelial ovarian, primary peritoneal, and fallopian tube cancers, collectively called "epithelial ovarian cancers" 5 , who fell into any of the 3 platinum categories outlined in the Introduction. Phase ii or iii rcts published in English that compared one systemic therapy option with another systemic therapy option or with a placebo were included. No minimum sample size was specified. The systematic review of the evidence focuses on systemic therapy and excludes intraperitoneal chemotherapy, hormonal therapy, or chemotherapy with bone marrow or stem-cell transplantation. A review of the titles and abstracts that resulted from the literature search was conducted by Erin Kennedy, Jennifer Salerno, and author NC. The remaining authors reviewed the articles considered for inclusion and agreed on the full-text articles to be included. 
Data Extraction and Assessment of Study Quality
Data were extracted by Erin Kennedy, Jennifer Salerno, and author NC and were audited by a project research assistant. The data elements were population, intervention, and outcomes information. The gr ade (Grading of Recommendat ions A ssessment, Development a nd Evaluation) process was used to assess the quality of included studies with respect to the critical and important outcomes 9 ; however, given the complexity and heterogeneity of the study designs and comparisons, grade was used as an overall critical appraisal guide. In addition, because of the heterogeneity of protocols, populations, and interventions in the included studies, a meta-analysis was not considered.
Search for Existing Guidelines
A search for existing guidelines was undertaken to determine whether an existing guideline could be adapted or endorsed. A priori, the Working Group recognized the prior version of the guideline developed by the Gynecologic Cancer Disease Site Group and published by the pebc 8 . Nine guidelines were identified. The Working Group felt that none of those guidelines were suitable for adaptation or endorsement because the guideline recommendations did not align with the Working Group's research question and methods.
Search for Existing Systematic Reviews and Primary Literature
No systematic reviews that met the inclusion criteria were identified. The reviews that were located were judged unsuitable because they were too old, could not be obtained, had inclusion criteria different from those defined for the present guideline, or included first-line treatments in their analysis.
The primary literature search yielded thirty-six primary research papers representing thirty phase ii or iii rcts that met the eligibility criteria . Phase iii studies that were of high quality and had a low risk of bias received more weight in determining the guideline recommendations presented here.
Six of the included studies were assessments of olaparib in populations of women with serous tumour h i stolog ies 12, 22, 25, 26, 29, 37 . Five st ud ies con sidered systemic treatment in patients with recurrent ovarian cancer 16, 21, 32, 33, 35 . Seven studies addressed systemic treatment in a platinum-sensitive population 10, 11, 15, 23, 31, 41, 44 . Twelve studies reported on patients with platinumresistant ovarian cancer 14, [17] [18] [19] 24, 30, 36, [38] [39] [40] 43, 45 . 
RECOMMENDATIONS, KEY EVIDENCE, AND INTERPRETATION OF THE EVIDENCE
Recommendation 1
Systemic therapy for recurrent ovarian cancer is not curative. As such, it is recognized that, to determine the optimal therapy, each patient has to be assessed individually in terms of recurrence, sensitivity to platinum, toxicity, ease of administration, and patient preference.
Recommendation 2
All patients should be offered the opportunity to participate in clinical trials, if appropriate.
Recommendation 3
With respect to chemotherapy for patients with platinumsensitive recurrent ovarian cancer, 
Key Evidence for Recommendation 3
A 976-patient study, calypso 46 , compared c-p w it h c-pld and found an improvement in pfs with the c-pld combination (11.4 months vs. 9.3 months, p = 0.005), a more favourable toxicity profile, no difference in os (although significantly more patients crossed over to the c-pld arm), and a superior crossover treatment rate in the c-p arm. Global qol scores did not differ between the groups 47 . A 672-patient study, ova-301 48 , compared pld with trabectedin-pld, and found a statistically significantly improved pfs with the combination therapy (7.3 months vs. 5.8 months, p = 0.019). Despite that finding, which implies the viability of the combination as a treatment option, the trabectedin-pld combination is not recommended at this time, based on the findings of no difference in qol 49 or os 50 , the lack of clinical significance of a 6-week pfs difference, the lack of comparison with the Gynecologic Cancer Intergroup standard of a taxane and a platinum agent 3 , and the elevated rate, in the combination group, of adverse events such as raised liver enzymes, nonfatal congestive heart failure, and neutropenia.
A study by Sehouli et al. 51 of topotecan compared with topotecan combined with other agents did not find a benefit with the combination therapy in a population of mainly platinum-sensitive women; thus, topotecan combination therapy is not recommended.
Two smaller trials that compared pld with gemcitabine showed no difference in pfs. A small significant difference in os was found in one trial (56 weeks for pld vs. 51 weeks for gemcitabine, p = 0.048) 52 . The adverse events profiles for the two agents differ, and therefore gemcitabine can be considered to be another option in this patient population, considering patient preference and previous toxicity 52, 53 .
Recommendation 4
Women with platinum-sensitive recurrent ovarian cancer should, after a discussion about the safety profile, be offered chemotherapy with biologics.
These targeted agents can be considered:
■ Bevacizumab combined with combination chemotherapy and as maintenance therapy ■ Cediranib administered during the chemotherapy and as maintenance therapy ■ For patients with known BRCA1 or BRCA2 mutations (somatic and germline), polyadp-ribose polymerase (parp) inhibitors are recommended as maintenance treatment after platinum-based chemotherapy for recurrent disease ■ For patients who are BRCA wild-type, niraparib can be considered as maintenance after platinum-based chemotherapy for recurrent disease.
Qualifying Statements for Recommendation 4
With the increase in evidence supporting the use of parp inhibitors in patients with homologous recombination deficiency mutations, consideration should be given to testing the BRCA status of all women with ovarian cancer at initial diagnosis. The parp inhibitors have been associated with an increase in pfs in patients with BRCA mutations, but without a significant improvement in os.
In women with wild-type BRCA, parp inhibitors have also been associated with a minor improvement in pfs.
Key Evidence for Recommendation 4
In the platinum-sensitive population of the oceans phase iii rct, the pfs for bevacizumab plus gemcitabine and carboplatin (bev+ct) was shown to be superior compared with carboplatin plus gemcitabine plus placebo (ct) [hazard ratio (hr): 0.48; 95% confidence interval (ci): 0.39 to 0.61]. The median pfs was 12.4 months in the bev+ct arm compared with 8.4 months in the ct arm 10 .
In the platinum-sensitive population of the moderatequality icon6 phase iii rct, the pfs for arm C with cediranib was shown to be superior compared with the reference arm A of platinum-based therapy plus placebo (hr: 0.56; 95% ci: 0.44 to 0.72). Median pfs was 11.0 months in the experimental arm and 8.7 months in the nonexperimental arm 11 .
Compared with placebo, niraparib was associated with a significantly prolonged pfs in platinum-sensitive patients with no germline BRCA mutations (hr: 0.45; 95% ci: 0.34 to 0.61; p < 0.001) 12 .
Interpretation of the Evidence for Recommendation 4
The listed recommendations are conditional in nature (that is, "can be considered") given the trade-off between the benefit (that is, pfs) weighed against the harms (that is, adverse effects).
Based on moderate-quality evidence in the oceans tria l 10, 13 , statistica lly signif ica nt ly increased risks for bev+ct compared with ct were shown for these adverse events: Notably, the confidence intervals for grade 3 or greater hypertension and proteinuria were very wide because of the few events (<5) occurring in the ct arm.
In the icon6 trial 11 , statistically significantly increased risks during the chemotherapy phase for the combined arms B and C of platinum-based chemotherapy (ct) plus cediranib compared with reference arm A of ct plus placebo were shown for these adverse events:
■ Grade 3 or greater fatigue: rr, 2.11; 95% ci, 1.07 to 4.11 ■ Grades 3-4 diarrhea: rr, 5.94; 95% ci, 1.45 to 24.34 ■ Grades 3-5 hypertension: rr, 3.32; 95% ci, 1.21 to 9.10 Notably, the confidence intervals for grades 3-5 diarrhea were very wide because of the few events (<5) in the reference ct-only arm.
Recommendation 5
With respect to patients having platinum-refractory or platinum-resistant recurrent ovarian cancer, ■ lower levels of response to treatment are expected for this group; the goals of treatment should therefore be to improve the patient's qol by extending the symptom-free interval, reducing symptom intensity, increasing pfs, and if possible, prolonging life. ■ monotherapy with a non-platinum agent should be considered given that no advantage appears to accrue to the use of non-platinum-containing combination chemotherapy in this group of patients. Single-agent paclitaxel, topotecan, pld, and gemcitabine have demonstrated activity in this patient population and are reasonable treatment options. ■ there is no evidence to support or refute the use of more than one line of chemotherapy in patients w ith platinum-refractor y or platinum-resistant recurrences. Many treatment options have shown modest response rates, but their benefit over best supportive care has not been studied in clinical trials. ■ bevacizumab combined with chemotherapy (pld, weekly paclitaxel, or topotecan) can be considered for women who meet the eligibility criteria of the aurelia phase iii rct (confirmed epithelial ovarian, fallopian tube, or primary peritoneal cancer that has progressed within 6 months of completion of 4 or more cycles of platinum-based therapy; age 18 years or greater; Eastern Cooperative Oncology Group performance status of 2 or less; and adequate liver, renal, and bone marrow function). 
Qualifying Statements for Recommendation 5
At the time this guideline was written, numerous targeted agents (in addition to vascular endothelial grow th factor inhibitors, PD-1 and PD-L1 inhibitors, and other immunotherapies) were under investigation and showing promise in early trials. It is likely that one or more of those agents will become part of the lexicon of treatment protocols in the near future, either independently or in combination with conventional chemotherapy.
Key Evidence for Recommendation 5
Based on moderate-quality evidence in the aurelia phase iii rct, the hr for pfs in women with platinumresistant recurrent ovarian cancer was 0.48 (95% ci: 0.38 to 0.60) for chemotherapy including pld, weekly paclitaxel, or topotecan with bevacizumab (bev+ct) compared with the same regimen without bevacizumab (ct). Median pfs was 6.7 months in the bev+ct arm compared with 3.4 months in the ct arm 14 .
Statistically significantly increased risks for bev+ct compared with ct were shown for these adverse events:
■ Grade 2 or g reater adverse event s, i nclud i ng hypertension, gastrointestinal perforation, and fistula or abscess: rr, 3.71; 95% ci, 2.03 to 6.78 14 ■ Grade 3 or g reater adverse event s i nclud i ng hypertension, proteinuria, gastrointestinal perforation, bleeding, thromboembolic event, wound healing, reversible posterior leucoencephalopathy syndrome, congestive heart failure, and cardiac disorders: rr, 2.64; 95% ci, 1.44 to 4.84 14 Based on very low-quality evidence, statistically significant improvements of 15% or more in abdominal or gastrointestinal symptoms were shown for bev+ct compared with ct (rr: 2.33; 95% ci: 1.37 to 3.97) 14 .
Interpretation of the Evidence for Recommendation 5
Based on moderate-quality evidence, a beneficial effect on pfs was associated with bev+ct.
The listed recommendation is conditional in nature (that is, "can be considered") because of the detection of adverse events with the use of bev+ct. Although based on low-quality evidence, the Gynecologic Cancer Disease Site Group accepts lower-tier evidence informing harms outcomes, thereby tempering the recommendation despite evidence for improved pfs.
Further Qualifying Statements
In several trials, parp inhibitors have been associated with a significant improvement in pfs, although the phase iii data in this drug class are limited. Based on current evidence, a conditional recommendation was made for parp inhibitors in the patient population positive for BRCA mutation or homologous recombination deficiency and in the non-BRCA population. Olaparib has been approved by the U.S. Food and Drug Administration for recurrent ovarian cancer with germline mutations.
There is increasing evidence to support the unique nature of the numerous histologic subtypes within ovarian cancer. As evidence increases, treatment regimens will be optimized by subtype. Those issues will be addressed in a pebc guideline currently under development.
IMPLEMENTATION CONSIDERATIONS
In June 2015, cediranib as monotherapy was withdrawn by AstraZeneca from consideration by the European Medicines Agency's Committee for Medicinal Products for Human Use. However, that decision does not affect cediranib as a combination treatment with other agents.
The Gynecologic Cancer Disease Site Group believes that patient preference should play a significant role in disease management in the setting of recurrent ovarian cancer. Because cure is seldom an endpoint in this circumstance, the attitude of the patient with respect to the risks and benefits of chemotherapy compared with palliation are relevant.
Currently, all women with high-grade serous ovarian cancer should be offered testing for BRCA1 and BRCA2. This germline testing has implications for timely access to genetic counselling services and lab results. The impending move to somatic testing will have implications for the funding of the pathology services that will test tissue. It is highly likely that other ovarian histologies will be candidates for testing in the future.
REVIEW AND UPDATE
Guidelines developed by the pebc are regularly reviewed and updated. Please visit the cco Web site (http://www. cancercare.on.ca) for the full evidence-based series report and subsequent updates.
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